Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device.
Excimer Therapies officially enters the market and will demonstrate the exciplex during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California. The event marks the first time the exciplex is available for sale in the U.S.
“We are hoping to help dermatologists offer an adjunct or alternative to the current therapies that treat the large patient populations suffering from psoriasis, atopic dermatitis, vitiligo and leukoderma,” says Excimer Therapies' CEO and President Fred Hill, in a news release.
The exciplex is a narrowband, 308-nanometer UVB excimer light system with patent-pending technology. It is touch-screen controlled, ergonomically designed, and weighs only two pounds. It has a large, 25-square-centimeter treatment window, producing a maximum output of 2,500 milliwatts, which can be adjusted to the patients' needs with the touch-screen controlled software, disposable masks and reducers. It also has a built-in programmable maximum erythema dose (MED) determination mode to help doctors determine the right MED dose of UVB for the patient quickly and easily.
Clarteis SAS recently received FDA clearance to market the device in the U.S. Clarteis also has both the CE Mark and ISO 13485 certification in Europe. The device is already distributed in 11 other countries, including Japan, India and Australia.